Background: The National Comprehensive Cancer Network (NCCN) Outcomes Database was created to assess concordance to evidence-and consensus-based guidelines and to measure adherence to quality measures on an ongoing basis. The Colorectal Cancer Database began in 2005 as a collaboration among 8 NCCN centers. Methods: Newly diagnosed colon and rectal cancer patients presenting to 1 of 8 NCCN centers between September 1, 2005, and May 21, 2008, were eligible for analysis of concordance with NCCN treatment guidelines for colorectal cancer and with a set of quality metrics jointly developed by ASCO and NCCN in 2007. Adherence rates were determined for each metric. Center-specific rates were benchmarked against mean concordance rates for all participating centers. Results: A total of 3443 patients were evaluable. Mean concordance rates with NCCN colorectal cancer guidelines and ASCO/NCCN quality measures were generally high (≥ 90%). However, relatively low mean concordance rates were noted for adjuvant chemotherapy treatment recommendations within 9 months of diagnosis of stage II to III rectal cancer (81%), and neoadjuvant chemoradiation in clinical T4 rectal primaries (83%). These low rates of concordance seemed to be consistent across centers. Conclusions: Adherence to guidelines and quality measures is generally high at institutions participating in the NCCN colorectal cancer database. Lack of documentation, patient refusal, delayed treatment initiation, and lack of consensus about whether treatment was essential were the primary reasons for nonconcordance. Measurement of concordance and the reasons for nonconcordance enable participating centers to understand and improve their care delivery systems. (JNCCN 2009;7:895-904) 
Background
The National Cancer Policy Board (NCPB) was established in 1997 in response to concerns about cancer care quality in the United States. 1 In 1999, the NCPB released Ensuring Quality Cancer Care with key recommendations, which suggested the use of evidence-based, systematically developed guidelines and "measurement and monitoring of the quality of care using a core set of quality measures." 2 The NCPB also recognized the need All participating institutions are National Cancer Institute (NCI)-designated comprehensive cancer centers, and were selected for participation in the NCCN CRC Outcomes Database project based on participation in prior database collection efforts. They include the 2 largest specialty cancer centers in the United States, encompass geographic diversity, and have a composition of patients similar to that seen at all 21 NCCN institutions. Other eligibility criteria included American Joint Committee on Cancer (AJCC; 6 th edition) stage I to IV colon or rectal cancer and histology of adenocarcinoma, including mucinous and signet ring adenocarcinoma. Patients who presented for a second opinion or those with earlystage cancer that was removed with a polypectomy were not eligible for participation in the database. The NCCN CRC Database project was reviewed by the Institutional Review Board (IRB) at each participating institution. Some study sites required individual patient informed consent forms for participation, whereas others considered this to be minimal risk research and permitted waivers of informed consent with demonstration of adequate privacy safeguards.
Data Collection
Data abstracted from medical records on eligible patients were collected longitudinally from the time of diagnosis. Data collected at baseline were patient sociodemographic characteristics, insurance status, information pertaining to comorbid conditions as ascertained using the Charlson Index, 13 and ECOG performance status as documented by a health provider at presentation.
To capture treatment and recurrence information, patients' medical records were systematically reviewed at 4, 8, and 12 months after presentation, and annually thereafter. At the 4-month assessment, information was obtained on clinical characteristics, such as clinical and pathologic staging (TNM), histology, tumor location, and tumor risk factors (including tumor grade, presence of lymphovascular or perineural invasion, tumor obstruction or perforation, number of lymph nodes removed and involved with tumor, and margin status based on pathology report from primary surgery). Extensive detail refor data systems that could capture information on individual patients to enable contemporary evaluation of practice patterns. 3 The NCPB report and recognition of important deficiencies in cancer care delivery has prompted numerous initiatives to define and measure the quality of cancer care. [4] [5] [6] One initiative is the NCCN Colorectal Cancer (CRC) Outcomes Database Project, which is part of the larger NCCN Outcomes Database that now encompasses several other diseases, including nonHodgkin's lymphoma and breast, lung, and ovarian cancers. With an estimated 150,000 new cases in 2007, CRC is the fourth most commonly diagnosed malignancy in the United States. 7, 8 Considering the high incidence of this disease and recent advancements in new, expensive treatments for CRC, expanding the NCCN Oncology Outcomes Project in 2005 to include primaries of the colon and rectum was considered timely. 9 From the outset, one of the main objectives of the NCCN CRC Outcomes Database was to evaluate patterns of care and concordance to guidelines and quality measures. Concordance analyses were based on the NCCN consensus-driven and evidence-based colon and rectal cancer guidelines. 10, 11 Additionally, in collaboration with ASCO and the American College of Surgeons, NCCN developed quality measures for breast, colon, and rectal cancers, forming the basis of the other aspect of our concordance analyses. This article reports our findings on concordance analyses according to the NCCN Clinical Practice Guidelines in Oncology: Colon and Rectal Cancers (in this issue; to view the most recent version of these guidelines, visit the NCCN Web site at www. nccn.org) and ASCO/NCCN Quality Measures.
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Methods
Subjects
Patients with newly diagnosed colon or rectal cancer presenting at NCCN centers between September 1, 2005, and May 21, 2008, were included. A consecutive series of patients aged 18 years or older were found eligible if they had received surgery, chemotherapy, or both at 1 of 8 NCCN member institutions. These institutions include City of Hope Comprehensive Cancer Center, Dana-Farber Cancer Institute, Fox Chase Cancer Center, Memorial Sloan-Kettering Cancer Center, The Ohio State University Compre-garding cancer-directed treatments was collected at each follow-up assessment. All treatments delivered at NCCN and outside institutions, including primary cancer-directed surgery, radiation therapy, and systemic therapy, were carefully captured during the chart abstraction process. Documented information pertaining to therapies administered in the inpatient and ambulatory setting was captured.
A unique aspect of the NCCN Outcomes Databases is the collection of reasons for lack of treatment delivery. If noted in the medical record, explicitly documented reasons for lack of performance of primary cancer surgery, or lack of delivery of chemotherapy or radiation therapy, were abstracted for each treatment type, thus facilitating the determination of the rationale behind not delivering recommended care.
Rigorous data quality assurance processes were maintained for the NCCN Outcomes Database Project, including initial and follow-up data management training for study personnel, online edit checking during Web-based data entry, programmed logic checks against the pooled data repository, routine quality assurance reports to each institution for the data managers to rectify, and onsite audits of a random sample of source documents against submitted data within the first few months of data collection (repeated annually). Each NCCN institution was audited for data completeness and quality at least twice between September 2005 and May 2008.
NCCN Guideline and ASCO/NCCN Quality Measure Concordance
The availability of detailed patient-level clinical and treatment information in the NCCN CRC Outcomes Database enabled measurement of concordance to guideline-directed care and evaluation of adherence to quality measures. Therapies administered at outside institutions and before recurrence were included in the concordance analyses. Care was assessed against the guideline in effect when it was delivered. Patients enrolled in a clinical trial who were eligible for a specific concordance analysis were deemed concordant.
Statistical Analysis
Baseline characteristics at presentation to the NCCN institution were summarized as descriptive statistics. For continuous variables, the median and range were reported. For categorical variables, the number and proportion of patients were reported for each category.
Eligibility for evaluation of guideline concordance was conditioned on follow-up to ensure sufficient time for initiation of treatments and documentation in the medical record. For primary surgery recommendations, minimum follow-up was 90 days after diagnosis; for adjuvant chemotherapy, at least 120 days of follow-up was required, For guidelines that included neoadjuvant therapy, follow-up was extended to 180 days postdiagnosis. Follow-up times for the ASCO/NCCN Quality Measure analyses were set according to the definition of each metric. In addition, if a patient transferred out of an NCCN institution, developed a new type of cancer, relapsed, or died within these timeframes, that patient was not evaluable for a specific guideline or quality measure recommendation.
Overall concordance rates for all NCCN institutions were summarized as the unweighted average percent concordance, defined as the number of patients considered concordant on each metric divided by the total number of evaluable patients. For centers with at least 10 evaluable patients for each concordance analysis, an institutional range of concordance reflected as a percentage (%) on a per-center basis (with the range listed from low to high percentage) was calculated. If only 1 institution had 10 or more evaluable patients, the institution range was denoted as n/a -% for that single institution.
Variation in guideline and quality measure concordance across NCCN institutions was examined by calculating the center-specific percent concordance. For ASCO/NCCN Quality Measures, the time trends for concordance rates were also examined by calculating the overall percent concordance based on year of diagnosis of the colon or rectal cancer. Lastly, to glean information on reasons for lack of treatment delivery in accordance with ASCO/ NCCN Quality Measures, the proportion of patients who did not receive the recommended care was calculated according to several broad categories, such as patient-(e.g., patient declined treatment), physician-(e.g., physician recommended against treatment), and system-level (e.g., delayed treatment). Table 1 details the demographic and clinical characteristics for 3443 patients who were evaluable for the guideline and quality measure concordance analyses.
Results
Study Cohort
relative to their proportion in Surveillance, Epidemiology and End Results (SEER). Table 2 shows adherence to the NCCN/ASCO Quality Measures for all centers combined. Overall adherence to recommended care equaled or exceeded 90% for 3 of the 4 quality metrics. The exception to the high rates noted earlier was a lower frequency of administration of adjuvant chemotherapy within 9 months of diagnosis in patients with stage II and III rectal cancer; the overall adherence rate for this metric was 81% (95% CI, 77%-85%). However, the overall proportion of patients who underwent postoperative adjuvant chemotherapy in stage II and III rectal cancer increased over time (Figure 1 ).
Adherence to NCCN/ASCO Quality Measures
Compared with a U.S. population-based sample in which the median age at diagnosis was 71 years, patients who presented to the NCCN institutions with newly diagnosed colon or rectal cancer were younger (median age, 60 years; range, 18-94 years).
14 Most participants had no comorbid conditions (70%), and a quarter had a Charlson comorbidity score of 1 to 2. These proportions were congruent with the ECOG performance status, for which most patients (78%) were fully active (ECOG performance status 0) and 12% had a performance status of 1 at presentation. Patients who were treated solely with local definitive primary treatment (polypectomy) were not included in the NCCN CRC Outcomes Database. Therefore, patients with stage I disease were underrepresented Table 3 categorizes the reasons patients did not receive quality measure-concordant therapy. Patient refusals were distinctly uncommon; more often treatment was deemed nonconcordant because the medical records did not document whether patients underwent therapy. In other cases, treatment was given but not within the timeframe specified by the quality metric. For example, among the 85 patients who were not treated according to the recommendation to undergo adjuvant chemotherapy within 9 months of stage II to III rectal cancer, 18% were treated with systemic therapy outside the recommended timeframe. The preponderance of these cases either experienced postoperative complications or were referred from outside centers, thus contributing to treatment delays. For most (72%), there was no documentation for the reason postoperative adjuvant treatment was omitted.
Notably, 77 of 85 (91%) patients who were not treated with postoperative adjuvant chemotherapy within 9 months of diagnosis underwent neoadjuvant chemoradiation. Nearly one quarter experienced complete pathologic response to induction chemoradiation and some tolerated neoadjuvant chemoradiation poorly. Although not always explicitly stated in the medical record, this seemed to be the primary reason for nonconcordance.
Variation in Adherence to NCCN/ASCO Quality Measures Across NCCN Institutions
Among the 8 participating NCCN institutions, no center seemed to be associated with consistently high or low rates of adherence to recommended care across NCCN/ASCO Quality Measures (Table 4 ). Still, a wide variation in institutional percent adherence rates was noted for the recommendation of adjuvant chemotherapy in locally advanced rectal cancer (58%-88%), with 5 centers reporting rates less than 85%. Although overall adherence was 90% for delivery of adjuvant chemotherapy in stage III colon cancer, notable center variation was also observed (77%-98%) because 1 center had lower adherence than the others. Table 5 shows the overall concordance by guideline for all centers combined, and the corresponding institutional concordance range was based on centerspecific percent concordance. The overall concordance rates were strikingly high across the evaluated guidelines. Notably, primary treatment recommendations for rectal cancer were followed with an adherence frequency exceeding 90%. Still, 8 patients (8%) with stage I rectal cancer were treated with a transanal excision (TAE) in the presence of at least 1 criterion indicating that it was not recommended as the definitive procedure.
NCCN Guideline Concordance
Concordance analyses of the appropriate use of adjuvant systemic treatment showed that patients with stage I (colon and rectal) cancers were rarely overtreated. In clinical stage IIA or III rectal cancers, most patients (97%) were treated with the recommended transabdominal resection with or without neoadjuvant therapy. Patients who received nonconcordant care for this guideline branch were predominantly treated with neoadjuvant therapy 
Discussion
Analysis of care delivered at 8 NCCN institutions showed that most patients treated for colon and rectal cancer at the NCI-designated comprehensive cancer centers received care in accordance with the NCCN Clinical Practice Guidelines in Oncology: Colon and Rectal Cancers (in this issue; to view the most recent version of these guidelines, visit the NCCN Web site at www.nccn.org) and ASCO/NCCN Quality Measures. Adherence rates for the quality measures equalled or exceeded 90% for 3 of 4 metrics. Except for one guideline, the 6 guidelines examined had overall mean concordance rates exceeding 90%. No single institution ranked consistently high or low across these measures. Still, the observed center variation for each measure and particularly the highest percent concordance for the only and did not undergo a primary cancer resection (80% of 15 discordant cases). The lowest overall concordance rate was observed for the guideline recommending neoadjuvant chemoradiation for clinical T4 rectal tumors (83%; Table 5 ). Most discordant patients (67%) did not undergo either chemotherapy or radiation in the neoadjuvant setting. The remaining proportion of discordant patients (33%) received only single-modality neoadjuvant therapy.
Finally, among patients with stage III colon cancer, most (92%) underwent the guideline recommended adjuvant chemotherapy, whereas only 2% were administered a combination of chemotherapy and a biologic in the adjuvant setting outside of a clinical trial. Still, given that 1 center had a concordance rate of 81% for this metric, these results leave some room for scrutiny. institutional range provided a benchmark for a level of achievable performance. 15 Exceptions to high rates of concordance are noteworthy because they present opportunities for quality improvement efforts. The recommendation for neoadjuvant chemoradiation therapy in clinical T4 rectal primaries was seen to be followed in 83% of cases in all centers combined. This relatively low rate of concordance seemed to be consistent across centers (institutional concordance range, 73%-80%). A parallel pattern emerged for the ASCO/ NCCN Quality Measure of postoperative adjuvant chemotherapy administration within 9 months from diagnosis in stage II and III rectal cancer, for which the overall concordance rate was 81%.
Most patients (90%) for whom care was nonconcordant with the postoperative adjuvant chemotherapy recommendation for rectal cancer had been treated with neoadjuvant combined modality therapy, and 34% had no residual disease. When a neoadjuvant approach is used in the setting of locally advanced disease, patients are committed to postoperative systemic chemotherapy because pretreatment nodal status is uncertain. This analysis shows that postoperative adjuvant chemotherapy is less consistent in the setting of locally advanced rectal cancer. Favorable downstaging appears to decrease patient or physician enthusiasm for postoperative treatment. This finding creates an opportunity for education surrounding postoperative management of rectal cancer.
In addition to these relatively low concordance rates, considerable variation in concordance was also seen across institutions for the adjuvant chemotherapy guideline treatment recommendation in stage III colon cancer (81%-100%). For this metric, one center underperformed compared with the remaining participating institutions. These examples signal opportunities for closer scrutiny towards quality improvement efforts.
Among currently implemented quality monitoring and improvement efforts, a semiannual analysis of concordance with the NCCN Colon and Rectal Cancers Guidelines (in this issue; available at www. nccn.org) and ASCO/NCCN Quality Measures is conducted across the participating institutions. These results encompass benchmarking an individual center performance against all centers combined. Each institution is specifically given a list of nonconcordant patients and reviews those records to identify further information regarding the reason for nonconcordance. In some cases, this may be a failure of documentation. The results are then reported to institutional quality assurance and clinical teams by the co-investigators. In addition, the NCCN CRC Database features patient-level concordance reporting that is refreshed nightly, therefore allowing patients deemed discordant to be identified and reviewed in a timely manner.
The results of strikingly high overall concordance rates-with most analyzed NCCN Colon and Rectal Cancers Guidelines (available at www.nccn. org) and ASCO/NCCN Quality Measures-are that using the medical record as the sole data source for the NCCN CRC Database limits the ability for a comprehensive NCCN guideline concordance analysis, because several of the guideline branches rely on determining the resectability of malignant disease. In our experience, this information was underreported in the medical chart. In addition, information on treatments received outside NCCN centers may have been incomplete. Although problems surrounding underreporting were mitigated by restricting the analysis to patients whose last assessment occurred at an NCCN institution, records pertaining to treatment delivery outside of NCCN centers may have been incomplete (e.g., unknown start dates for chemotherapy or radiation therapy). This bias toward lower concordance rates may partly explain lower concordance rates at some of the participating centers.
In conclusion, the NCCN CRC Database is an important vehicle for quality monitoring and imcongruent with the experience of the NCCN Breast Cancer Database, which also show generally high mean overall concordance rates to the NCCN Clinical Practice Guidelines in Oncology: Breast Cancer (to view the most recent version of these guidelines, visit the NCCN Web site at www.nccn.org). 15 In addition, similar to the NCCN CRC patient population, most women with breast cancer who present to NCCN centers receive care according to the recommendations of the ASCO/NCCN Quality Measures. While the quality of cancer care delivered at NCCN institutions appears to be high, components of care were identified that warrant further scrutiny on both a systemic level and at individual centers.
Although the number of guidelines that were analyzed in this report was limited, with longer patient follow-up, this process will be expanded to include a wider array of guideline recommendations, including posttreatment surveillance. However, we acknowledge provement efforts, because it captures the requisite clinical detail and care delivered for patients with colon and rectal cancers who present to participating NCCN institutions. Adherence to guideline and quality measure recommendations was found to be generally high at these centers. Above all, key opportunities for improvement in quality of care were identified, including postoperative delivery of adjuvant chemotherapy in stage II and III rectal cancer within 9 months of diagnosis and the administration of neoadjuvant chemoradiation in clinical T4 rectal primaries. With longer follow-up, a still greater potential exists to assess outcomes of cancer care across leading United States cancer centers. 
